Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
By P. Brown, S. Pugh, N. Laack, J. Wefel, D. Khuntia, C. Meyers, A. Choucair, S. Fox, J. Suh, D. Roberge and 4 more. Neuro-Oncology, 2013
857 citations recorded by the source corpus.
Subfields: Critical Care and Intensive Care Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1045aa8701ec9460f89e132f1f2db104563e82d3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Planchard
- P. Brown
- V. Gondi
- S. Popat
- S. Pugh
- K. Kerr
- W. Tomé
- S. Novello
Citations in the corpus
- Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Neuroprotective agents have not shown a convincing role and are not recommended for routine use [II, C], with a small phase III trial of memantine on 149 assessable patients (RTOG 0614) suggesting benefit [268].”
- Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. (2020, methodology): “Several-fold reduction in radiation dose to hippocampi (yellow) using (A) hippocampal avoidant whole-brain radiotherapy (HA-WBRT) v (B) conventional WBRT. 1020 © 2020 by American Society of Clinical Oncology Volume 38, Issue 10 Downloaded from ascopubs.org by 207.241.229.224 on April 25, 2021 from 2”